ZA200704394B - Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection - Google Patents
Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injectionInfo
- Publication number
- ZA200704394B ZA200704394B ZA200704394A ZA200704394A ZA200704394B ZA 200704394 B ZA200704394 B ZA 200704394B ZA 200704394 A ZA200704394 A ZA 200704394A ZA 200704394 A ZA200704394 A ZA 200704394A ZA 200704394 B ZA200704394 B ZA 200704394B
- Authority
- ZA
- South Africa
- Prior art keywords
- beta
- lactamase
- compositions
- normally
- sodium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 108090000204 Dipeptidase 1 Proteins 0.000 title abstract 2
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract 2
- 102000006635 beta-lactamase Human genes 0.000 title abstract 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract 2
- 238000002347 injection Methods 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 2
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 abstract 2
- 229960000479 ceftriaxone sodium Drugs 0.000 abstract 2
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960000614 sulbactam sodium Drugs 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229960004755 ceftriaxone Drugs 0.000 abstract 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 229960005256 sulbactam Drugs 0.000 abstract 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 abstract 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2411DE2004 | 2004-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200704394B true ZA200704394B (en) | 2008-09-25 |
Family
ID=35789266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200704394A ZA200704394B (en) | 2004-12-02 | 2007-05-29 | Compositions for combating beta-lactamase-mediated antiboitic resistance using beta-lactamase inhibitors useful for injection |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8273732B2 (enExample) |
| EP (1) | EP1841432B1 (enExample) |
| JP (1) | JP5269415B2 (enExample) |
| KR (2) | KR20070067189A (enExample) |
| CN (1) | CN101060846A (enExample) |
| AT (1) | ATE476981T1 (enExample) |
| AU (1) | AU2005310888B2 (enExample) |
| BR (1) | BRPI0517128A (enExample) |
| CY (1) | CY1110886T1 (enExample) |
| DE (1) | DE602005022939D1 (enExample) |
| DK (1) | DK1841432T3 (enExample) |
| ES (1) | ES2349301T3 (enExample) |
| HR (1) | HRP20100591T1 (enExample) |
| MX (1) | MX2007006540A (enExample) |
| NZ (1) | NZ555075A (enExample) |
| PL (1) | PL1841432T3 (enExample) |
| PT (1) | PT1841432E (enExample) |
| RS (1) | RS51506B (enExample) |
| RU (1) | RU2397768C2 (enExample) |
| SI (1) | SI1841432T1 (enExample) |
| UA (1) | UA91204C2 (enExample) |
| WO (1) | WO2006059344A1 (enExample) |
| ZA (1) | ZA200704394B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010176A (ko) * | 2001-07-25 | 2003-02-05 | 이병두 | 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| CN101537009B (zh) * | 2009-04-30 | 2010-09-15 | 海口奇力制药股份有限公司 | 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| EP3412289A1 (en) * | 2011-05-28 | 2018-12-12 | Wockhardt Limited | Antibacterial compositions |
| EP2768503A1 (en) * | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| MY169816A (en) | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| EP2858636B1 (en) | 2012-06-07 | 2018-09-05 | Childrens Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
| US20150306076A1 (en) * | 2012-09-27 | 2015-10-29 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
| MX2016010699A (es) | 2014-02-18 | 2017-10-11 | Children's Hospital Los Angeles | Composiciones y metodos para tratar neutropenia. |
| EP3125887A1 (en) * | 2014-03-29 | 2017-02-08 | Wockhardt Limited | Pharmaceutical compositions comprising cefepime or sulbactam |
| SG11201509950TA (en) * | 2014-04-03 | 2016-01-28 | Kewpie Kabushiki Kaisha Also Trading As Kewpie Corp | Injection fluid bag and injection preparation |
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| JP6891275B2 (ja) * | 2016-11-02 | 2021-06-18 | 湘北威爾曼制薬股▲分▼有限公司Ｘｉａｎｇｂｅｉ Ｗｅｌｍａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ | セフトリアキソンナトリウムとスルバクタムナトリウムからなる組成物 |
| CN111249284B (zh) * | 2016-11-03 | 2022-10-04 | 湘北威尔曼制药股份有限公司 | 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠 |
| RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
| EP4272831A3 (en) | 2018-08-09 | 2024-02-21 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP4262860A4 (en) | 2020-12-17 | 2025-11-12 | Idexx Lab Inc | DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER |
| WO2025165991A1 (en) * | 2024-01-31 | 2025-08-07 | The Penn State Research Foundation | Biopolymeric anti-antibiotics and methods for making and using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630510B1 (en) * | 1999-10-28 | 2003-10-07 | Merck & Co., Inc. | Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| PL1468697T3 (pl) * | 2003-04-14 | 2008-05-30 | Wyeth Corp | Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań |
-
2005
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/sr unknown
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en not_active Ceased
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Ceased
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de not_active Expired - Lifetime
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en not_active Expired - Lifetime
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko not_active Expired - Fee Related
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es not_active Expired - Lifetime
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
-
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
-
2010
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
-
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005022939D1 (de) | 2010-09-23 |
| RU2007124325A (ru) | 2009-01-10 |
| WO2006059344A1 (en) | 2006-06-08 |
| KR20090101514A (ko) | 2009-09-28 |
| US8273732B2 (en) | 2012-09-25 |
| PT1841432E (pt) | 2010-10-25 |
| JP2008521884A (ja) | 2008-06-26 |
| HRP20100591T1 (hr) | 2010-12-31 |
| SI1841432T1 (sl) | 2011-02-28 |
| WO2006059344B1 (en) | 2006-11-02 |
| EP1841432A1 (en) | 2007-10-10 |
| KR20070067189A (ko) | 2007-06-27 |
| CN101060846A (zh) | 2007-10-24 |
| US9012442B2 (en) | 2015-04-21 |
| DK1841432T3 (da) | 2010-12-06 |
| BRPI0517128A (pt) | 2008-09-30 |
| RU2397768C2 (ru) | 2010-08-27 |
| ES2349301T3 (es) | 2010-12-29 |
| EP1841432B1 (en) | 2010-08-11 |
| US20100160277A1 (en) | 2010-06-24 |
| PL1841432T3 (pl) | 2011-01-31 |
| KR101244362B1 (ko) | 2013-03-18 |
| JP5269415B2 (ja) | 2013-08-21 |
| NZ555075A (en) | 2011-02-25 |
| UA91204C2 (ru) | 2010-07-12 |
| US20130023512A1 (en) | 2013-01-24 |
| AU2005310888A1 (en) | 2006-06-08 |
| RS51506B (sr) | 2011-06-30 |
| CY1110886T1 (el) | 2015-06-10 |
| ATE476981T1 (de) | 2010-08-15 |
| AU2005310888B2 (en) | 2011-01-06 |
| MX2007006540A (es) | 2008-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110886T1 (el) | Συνθεσεις για την καταπολεμηση της αντοχης στα αντιβιοτικα με μεσολαβηση β-λακταμασης, χρησιμοποιωντας αναστολεις β-λακταμασης χρησιμους για ενεση | |
| JP7245289B2 (ja) | 細菌感染症の処置方法 | |
| CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
| WO2007112000A3 (en) | Treatment of pain | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| JP2015147783A (ja) | メチルナルトレキソンを含む医薬処方物 | |
| CA2597812A1 (en) | Parenteral combination therapy for infective conditions with drug resistant bacterium | |
| NO20071711L (no) | Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel | |
| Parikh et al. | Preventive analgesia: Effect of small dose of ketamine on morphine requirement after renal surgery | |
| JP7436206B2 (ja) | 細菌感染症を処置する方法 | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| TW200639159A (en) | Treatment of pain | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| JP2008540515A (ja) | 嚢胞性線維症を含む重症感染症の処置および管理 | |
| MXPA05007601A (es) | Composiciones anti-protozoos que comprenden diclazuril. | |
| WO2022177968A8 (en) | Therapeutic methods | |
| CA2633077A1 (en) | Solid-state form of amg 706 and pharmaceutical compositions thereof | |
| WO2005092442B1 (en) | Method and compositions for treatment of chronic neuropathic pain | |
| EP2979694A1 (en) | Succinic acid compounds for use in bacterial infections | |
| CN1709263A (zh) | 抗菌素组合物 | |
| JP2017508769A5 (enExample) | ||
| Vergidis et al. | Beta-Lactamase Inhibitors | |
| Thursky | 17 Piperacillin–Tazobactam | |
| CN101897703A (zh) | 一种将厄他培南及β-内酰胺酶抑制剂作为有效成分的用于治疗结核的混合制剂 |